AMENDMENTS TO THE CLAIMS PURSUANT TO REVISED 37 CFR § 1.121

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

1. (Currently Amended) An aptamer-toxin conjugate therapeutic agent comprising a targeting moiety conjugated to a cytotoxic moiety wherein said targeting moiety is an aptamer specific for PSMA (Prostate Specific Membrane Antigen).

2. (Cancelled)

3. (Cancelled)

4. (Currently Amended) The therapeutic agent of ~~claim 2~~ claim 1 wherein said cytotoxic moiety is ~~selected from the group consisting of a cytotoxic peptide, a cytotoxic protein,~~ a small molecule chemotherapeutic agent~~, and a radioisotope therapeutic molecule~~.

5. (Withdrawn) The therapeutic agent of claim 3 wherein said cytotoxic moiety is selected from the group consisting of a cytotoxic peptide, a cytotoxic protein, a small molecule chemotherapeutic agent, and a radioisotope therapeutic molecule.

6. (Original) The therapeutic agent of claim 4, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.

7. (Withdrawn) The therapeutic agent of claim 5, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.

8. (Withdrawn) The therapeutic agent of claim 4 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.

9. (Withdrawn) The therapeutic agent of claim 5 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.

10. (Currently Amended) An aptamer-drug conjugate comprising one or more aptamers, wherein at least one aptamer is specific for a PSMA (Prostate Specific Membrane Antigen), and a drug linked by a linker and having the formula: $(aptamer)_n$ -- linker -- $(drug)_m$, wherein n is between 1 and 10 and m is between [[0]] 1 and 20.

11. (Cancelled)

12. (Withdrawn) The aptamer-drug conjugate of claim 10, wherein at least one of the one or more aptamers is specific for a target selected from the group consisting of PSMA, PSCA, e-selectin, an ephrin, ephB2, cripto-1, TENB2 (TEMFF2), ERBB2 receptor (HER2), MUC1, CD44v6, CD6, CD19, CD20, CD22, CD23, CD25, CD30, CD33, CD56, IL-2 receptor, HLA-DR10β subunit, EGFRvIII, MN antigen, caveolin-1 and nucleolin the target PSMA.

13. (Original) The aptamer-drug conjugate of claim 10, wherein the drug is a cytotoxin.

14. (Currently Amended) The aptamer-drug conjugate of claim 10, wherein the drug is ~~selected from the group consisting of a calicheamicin, a maytansinoid,~~ a vinca alkaloid~~, a cryptophycin, a tubulysin, dolastatin 10, dolastatin 15, auristatin E, rhizoxin, epothilone B, epithilone D, taxoids and variants thereof~~.

15. (Currently Amended) The aptamer-drug conjugate of claim 10, wherein the drug is ~~selected from the group consisting of Nac γ DMH, Nac γ NHS, maytansine, May NHS,~~ desacetyl vinblastine 3-carboxhydrazide (DAVCH)~~, desacetyl vinblastine 4 O succinate (DAVS), cryptophycin 52, and crypthophycin 52 amine (Cryp NH2)~~.

16. (Original) The aptamer-drug conjugate of claim 10, wherein the linker comprises one or

more nucleophilic moieties, one or more electrophilic moieties or combinations thereof.

17. (Original) The aptamer-drug conjugate of claim 10, wherein the linker is selected from the group consisting of a Boc-protected amine, a Boc-protected amine on a heterobifunctional linker, a nucleophilic dendrimer, an electrophilic dendrimer and an electrophilic comb polymer.

18. (Original) The aptamer-drug conjugate of claim 10, wherein the linker is selected from the group consisting of Boc-NH2-PEG-NHS, an erythritol dendrimer, an octa-polyethylene glycol dendrimer and comb polymer.